Astex
University of Cambridge spinout, now part of Taiho Oncology, Inc., specializing in fragment-based drug discovery for oncology and CNS disorders.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor | €0.0 | round |
| investor | €0.0 | round | |
| investor | €0.0 Valuation: €0.0 | round | |
| investor | €0.0 | round | |
N/A | Merger | ||
| Total Funding | 000k | ||
| GBP | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | 2 % | 30 % | 6 % | 3 % | 17 % | 27 % | 73 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | 17 % | 39 % | 38 % | 38 % | 43 % | 56 % | 60 % |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article
Related Content
Astex Pharmaceuticals specializes in the discovery and development of innovative cancer therapies. The company operates in the biopharmaceutical sector, focusing on creating new drugs to improve patient outcomes. Astex serves major pharmaceutical companies through collaboration and license agreements, contributing to the development of multiple drugs in preclinical and clinical stages. The business model revolves around research and development (R&D) partnerships, where Astex collaborates with leading pharma companies to bring new drugs to market. Revenue is generated through milestone payments, royalties, and licensing fees from these partnerships. The company has successfully brought three approved drugs to market, showcasing its expertise in drug discovery and development. Astex aims to attract and retain talented individuals passionate about improving global health through innovative products and services.
Keywords: cancer therapies, drug discovery, biopharmaceutical, R&D partnerships, clinical development, milestone payments, royalties, licensing fees, patient outcomes, innovative products.
